BTIG Research Issues Pessimistic Forecast for Billiontoone (NASDAQ:BLLN) Stock Price

Billiontoone (NASDAQ:BLLN) had its target price decreased by BTIG Research from $160.00 to $140.00 in a research note issued on Thursday, MarketBeat reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target would indicate a potential upside of 90.45% from the company’s current price.

A number of other research analysts also recently issued reports on the stock. Jefferies Financial Group began coverage on shares of Billiontoone in a research report on Monday, December 1st. They set a “hold” rating and a $117.00 target price on the stock. Wall Street Zen upgraded shares of Billiontoone to a “hold” rating in a research report on Saturday, November 15th. JPMorgan Chase & Co. dropped their price target on shares of Billiontoone from $150.00 to $145.00 and set an “overweight” rating for the company in a research note on Wednesday, December 10th. Stifel Nicolaus assumed coverage on shares of Billiontoone in a report on Monday, December 1st. They issued a “buy” rating and a $145.00 price objective on the stock. Finally, Weiss Ratings began coverage on shares of Billiontoone in a research note on Tuesday, February 3rd. They issued a “sell (d)” rating on the stock. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Billiontoone currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.57.

Billiontoone Price Performance

NASDAQ BLLN opened at $73.51 on Thursday. The firm has a market cap of $3.36 billion and a PE ratio of 735.10. Billiontoone has a 52 week low of $66.00 and a 52 week high of $138.70. The company has a fifty day moving average price of $85.55.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings results on Wednesday, March 4th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.07. The firm had revenue of $96.05 million for the quarter, compared to analyst estimates of $85.85 million. The firm’s revenue was up 113.0% compared to the same quarter last year.

Hedge Funds Weigh In On Billiontoone

Several institutional investors have recently modified their holdings of the stock. Adams Street Partners LLC acquired a new position in shares of Billiontoone during the 4th quarter worth about $140,063,000. Baillie Gifford & Co. acquired a new stake in shares of Billiontoone in the 4th quarter valued at approximately $103,786,000. Price T Rowe Associates Inc. MD bought a new position in Billiontoone during the 4th quarter worth approximately $39,717,000. JPMorgan Chase & Co. bought a new position in Billiontoone during the 4th quarter worth approximately $32,078,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Billiontoone during the fourth quarter valued at approximately $18,631,000.

Trending Headlines about Billiontoone

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q4 earnings beat and rapid revenue growth — BillionToOne reported $0.11 EPS vs. $0.04 consensus and revenue of $96.05M (vs. $85.85M est.), with revenue up ~113% year-over-year; results and commentary point to accelerating demand. View Press Release
• Positive Sentiment: Raised FY‑2026 revenue guidance — company lifted 2026 revenue guidance to $430M–$445M vs. consensus near $356M, implying materially stronger top‑line growth than analysts expected. Press Release
• Positive Sentiment: Earnings call & investor materials highlight strategy and growth drivers — management commentary and the slide deck underscored durable revenue expansion and product/market traction that support the raised guidance. Earnings Highlights
• Positive Sentiment: Analyst support: Guggenheim reaffirmed a “buy” with a $120 PT — another buy-side vote that can buoy sentiment despite mixed firm-level price target moves. Benzinga
• Positive Sentiment: Positive coverage piece framing BLLN as an attractive investment — broader bullish narratives and coverage can amplify buying interest following the beat and guidance lift. Article
• Neutral Sentiment: Analyst deep‑dive and metric comparisons — outlets (e.g., Zacks) are parsing metrics vs. estimates and prior periods; useful for modeling but not new catalyst. Zacks
• Neutral Sentiment: Q4 snapshot pieces summarize results for retail/institutional readers — helpful context but unlikely to move price independently. LMOnline
• Neutral Sentiment: Short‑interest data appears anomalous/unchanged (reports show zeros/NaN); no clear short squeeze signal from these feeds. (Data quality issue; monitor official FINRA reports.)
• Negative Sentiment: Wells Fargo cut its price target to $90 and set an “equal weight” rating — a downgrade in conviction from that shop could cap near‑term upside and weigh on sentiment for more conservative investors. Benzinga
• Negative Sentiment: BTIG trimmed its target from $160 to $140 (still a “buy”) — target cuts reduce the extent of analyst-driven upside, even if the rating remains positive. Street Insider

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.